DLAT

Across TCGA pan-cancer cohorts, DLAT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DLAT data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DLAT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DLAT expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where DLAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.908	0.672	.011	6	view →
PDAC	DFS	Median	All	0.814	0.635	.018	4	view →
CCRCC	OS	Median	II,III,IV	1.000	0.449	.032	3	view →
LSCC	OS	Quartile	All	1.000	0.949	.041	2	view →
GBM	DFS	Quartile	All	0.866	0.688	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DLAT–HNSC (DFS)

Open the HNSC breakdown →